大咖对话第4期(音频):诺华Nikolai Naoumov博士-AI数字病理学的对话
Episode 4 with Dr. Nikolai Naoumov - Dialogues on AI Digital Pathology.
In this episode, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases).
Dr. Nikolai Naoumov
Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases.
Dr Nikolai Naoumov is an Adviser for Clinical Research and Drug
Development in Liver Diseases at Novartis. Additionally, Nikolai has
been an adviser for research organizations, pharma companies, the
Foundations for Liver Research in the UK and in Switzerland.
Nikolai
is a physician-scientist with a professional career combining academic
research, clinical care and drug development – all focused on liver
diseases. He is a Fellow of the Royal College of Physicians (London) and
also the Royal College of Pathologists (UK), and has led research teams
at King’s College Liver Unit and subsequently as Professor of
Hepatology at University College London.
▲ A picture of Nikolai Naoumov, Ph.D.
With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai is here to talk about the impact of AI digital pathology in drug development efforts for NASH.
新加坡医疗科技公司HistoIndex,是杭州筹图科技有限公司的母公司,我们利用人工智能的图像分析技术和全球独创的无染色成像技术相结合应用于疾病进展的评价,特别是NASH新药开发的病理评价中。目前该技术平台已经在NASH临床前的多个动物模型和多个II,III期临床试验上做了深入研究和算法验证,已经参与完成近四十家国际国内知名药企、大型CRO公司和科研机构主办的相关试验。
那就赶紧来关注我们
长按二维码 关注我们
有问题请联系我们
热线电话:
4009-6565-83